Modular production facilities 'the future of all biologics,' says GE

By Dan Stanton contact

- Last updated on GMT

GE: Modular production facilities 'the future of all biologics'

Related tags: Monoclonal antibodies, Biotechnology

Fresh from completing an off-the-shelf JHL plant and signing a $350m facility deal with Pfizer, GE believes modular bioprocessing could be the future. 

General Electric (GE) announced its Q2 2016 earnings last week and reported a growth of 26% year-on-year in its bioprocessing business, incorporated within the firm’s GE Healthcare subsidiary.

During the quarter, the business - focused on upstream and downstream biomanufacturing equipment and services - hit several milestones based on its modular facility platform KUBio including the opening of a biologics plant in Wuhan, China and the striking of a strategic partnership with Pfizer.

“We believe these modularised bioprocess facilities will be the future of all biologics,”​ GE’s CFO Jeffrey Bornstein said in a conference call last Friday (transcript here​).

The Wuhan facility, built in partnership with Chinese biopharma firm JHL, became the world’s largest modular monoclonal antibody production plant​ when it opened in May, and validated the KUBio platform by delivering a fully functioning cGMP biomanufacturing facility within 18 months – far quicker than the typical three year build for a traditional site.

Meanwhile, the June deal with Pfizer​ – part of Pfizer’s $350m (€315m) investment into a new biosimilars plant – will see GE build a modular facility in Hangzhou, China equipped with multiple 2,000L single-use bioreactors to support the pharma giant’s biosimilar portfolio.

The concept of a modular bioprocessing plant has been discussed for a number of years​ as drugmakers look to more efficient and flexible ways to address shift from the blockbuster drug development model to more targeted, niche therapeutics.

For the three months ending June 30, GE Healthcare reported sales of $4.5bn, though as well as bioprocessing, this incorporates imaging and ultrasound systems, and a number of life sciences products including spectrophotometry, electrophoresis, quantitive imaging and blotting.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

CadenceILC_610x343

Inline concentration improves process economics

Pall Biotech | 15-Jun-2018 | Case Study

Would you like to enhance your downstream process, increase production capacity and reduce costs? This case study application note demonstrates how implementing...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars